# Vitamin B12a Vasoplegic Syndrome

> **NCT03735316** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 8 (actual)

## Conditions studied

- Vasoplegic Syndrome

## Interventions

- **DRUG:** Hydroxocobalamin
- **PROCEDURE:** Cardiopulmonary Bypass
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03735316
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-25
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Insufficient recruitment over study period
- **Last updated:** 2023-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03735316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03735316, "Vitamin B12a Vasoplegic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03735316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*